MA32729B1 - Derives d'acide 1-amino-2-cyclobutylethylboronique - Google Patents

Derives d'acide 1-amino-2-cyclobutylethylboronique

Info

Publication number
MA32729B1
MA32729B1 MA33796A MA33796A MA32729B1 MA 32729 B1 MA32729 B1 MA 32729B1 MA 33796 A MA33796 A MA 33796A MA 33796 A MA33796 A MA 33796A MA 32729 B1 MA32729 B1 MA 32729B1
Authority
MA
Morocco
Prior art keywords
amino acid
acid derivatives
relates
compositions
methods
Prior art date
Application number
MA33796A
Other languages
Arabic (ar)
English (en)
Inventor
Paul E Fleming
Jing Li
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA32729B1 publication Critical patent/MA32729B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

L'invention concerne de nouveaux composés utilisés comme inhibiteurs de protéasome. L'invention concerne également de compositions pharmaceutiques comprenant les composés de l'invention et des procédés d'utilisation de ces compositions pour traiter des maladies diverses.
MA33796A 2008-09-29 2011-04-26 Derives d'acide 1-amino-2-cyclobutylethylboronique MA32729B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19461408P 2008-09-29 2008-09-29
PCT/US2009/005324 WO2010036357A1 (fr) 2008-09-29 2009-09-25 Dérivés d’acide 1-amino-2-cyclobutylethylboronique

Publications (1)

Publication Number Publication Date
MA32729B1 true MA32729B1 (fr) 2011-10-02

Family

ID=41426361

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33796A MA32729B1 (fr) 2008-09-29 2011-04-26 Derives d'acide 1-amino-2-cyclobutylethylboronique

Country Status (25)

Country Link
US (3) US8664200B2 (fr)
EP (1) EP2346882B1 (fr)
JP (3) JP5736314B2 (fr)
KR (1) KR101739470B1 (fr)
CN (2) CN102203103A (fr)
AR (1) AR075090A1 (fr)
AU (1) AU2009297113B2 (fr)
BR (1) BRPI0919447B8 (fr)
CA (1) CA2739375C (fr)
CL (1) CL2011000653A1 (fr)
CO (1) CO6362015A2 (fr)
CR (2) CR20160475A (fr)
DO (1) DOP2011000086A (fr)
EA (1) EA030539B1 (fr)
EC (1) ECSP11011011A (fr)
IL (1) IL211983A0 (fr)
MA (1) MA32729B1 (fr)
MX (1) MX2011003317A (fr)
MY (1) MY166653A (fr)
NZ (2) NZ606001A (fr)
SG (1) SG194388A1 (fr)
TW (2) TW201024313A (fr)
UA (1) UA105503C2 (fr)
WO (1) WO2010036357A1 (fr)
ZA (1) ZA201203615B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2623113T (pt) 2005-11-09 2017-07-14 Onyx Therapeutics Inc Compostos para inibição de enzimas
SI2041158T1 (sl) 2006-06-19 2013-09-30 Onyx Therapeutics, Inc. Peptidni epoksiketoni za inhibicijo proteasomov
TWI501773B (zh) 2007-10-04 2015-10-01 Onyx Therapeutics Inc 結晶肽環氧酮蛋白酶抑制劑以及胺基酸酮環氧化物之合成
MX2010013642A (es) 2008-06-17 2010-12-21 Millennium Pharm Inc Compuestos de ester boronato y composiciones farmaceuticas de los mismos.
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
MX2012010017A (es) * 2010-03-01 2012-10-01 Onyx Therapeutics Inc Compuestos de para la inhibicion de inmunoproteasomas.
AR080863A1 (es) 2010-03-31 2012-05-16 Millennium Pharm Inc Derivados del acido1-amino-2-ciclopropiletilboronico, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer.
JP6286358B2 (ja) 2011-11-11 2018-02-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
CA2855356A1 (fr) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarqueurs de la sensibilite a des inhibiteurs du proteasome
SG11201403254QA (en) * 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
WO2013112601A1 (fr) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Méthodes de traitement du cancer
WO2014011695A2 (fr) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Promédicaments d'inhibiteurs d'époxy cétone protéase peptidique
US9464098B2 (en) * 2012-12-03 2016-10-11 Hoffmann-La Roche Inc. Substituted triazole boronic acid compounds
CN105705149A (zh) 2013-10-03 2016-06-22 米伦纽姆医药公司 用于预防或治疗系统性红斑狼疮和/或狼疮性肾炎的方法
WO2015106200A2 (fr) 2014-01-10 2015-07-16 Cornell University Dipeptides utilisés en tant qu'inhibiteurs des immunoprotéasomes humains
KR102509950B1 (ko) 2014-05-20 2023-03-14 밀레니엄 파머슈티컬스 인코퍼레이티드 일차 암 치료법 후 사용하기 위한 붕소-함유 프로테아좀 저해제
EP3177292B1 (fr) 2014-08-07 2020-11-25 Mayo Foundation for Medical Education and Research Composés et méthodes de traitement du cancer
CN114796207A (zh) 2014-08-18 2022-07-29 康奈尔大学 作为人免疫蛋白酶体的抑制剂的二肽模拟物
KR102450583B1 (ko) * 2014-10-01 2022-10-04 메르크 파텐트 게엠베하 보론산 유도체
ES2811273T3 (es) * 2014-10-01 2021-03-11 Merck Patent Gmbh Derivados del ácido borónico
AU2015327412B2 (en) * 2014-10-01 2020-01-16 Merck Patent Gmbh Boronic acid derivatives
JP6662865B2 (ja) * 2014-10-01 2020-03-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ボロン酸誘導体
KR20180064427A (ko) 2015-10-15 2018-06-14 코넬 유니버시티 프로테아좀 억제제 및 이의 용도
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
CN109476637B (zh) 2016-06-21 2022-02-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
CA3054572A1 (fr) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Composes et methodes de traitement du cancer
EP3694605A4 (fr) 2017-10-11 2021-10-27 Cornell University Inhibiteurs peptidomimétiques du protéasome
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (fr) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Inhibiteurs de la rénine
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
EP0583536B1 (fr) 1992-08-14 1997-03-05 The Procter & Gamble Company Compositions détergents liquides contenant de l'acide borique
US5935944A (en) 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
IL131410A0 (en) 1997-02-15 2001-01-28 Proscript Inc Pharmaceutical compositions for treating infarcts through inhibition of nf-kappab
AU9580098A (en) 1997-09-25 1999-04-12 Millennium Pharmaceuticals, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
EP1037626A1 (fr) 1997-12-16 2000-09-27 Cephalon, Inc. Inhibiteurs de protease multicatalytique, utiles en tant qu'agents antitumoraux
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
EP3078667B1 (fr) 2001-01-25 2018-11-21 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation de composés d'acide boronique
BR0210112A (pt) 2001-05-30 2004-06-08 Novartis Ag Derivados do ácido 2-{[n-(2-amino-3-(heteroarila ou arila)propionil)-aminoacil]-amino}-alquilborÈnico
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
WO2003059898A2 (fr) 2002-01-08 2003-07-24 Eisai Co. Ltd. Analogues d'eponemycine et d'epoxomicine et leurs utilisations
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
CN1867572B (zh) * 2003-08-14 2012-03-28 赛福伦公司 蛋白酶体抑制剂及其使用方法
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
EA012927B1 (ru) 2004-03-30 2010-02-26 Миллениум Фармасьютикалз, Инк. Синтез эфиров бороновой кислоты и кислотных соединений
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR20080030079A (ko) 2005-07-05 2008-04-03 트러스티즈 오브 터프츠 칼리지 섬유아세포 활성 단백질 알파의 억제제
WO2007089618A2 (fr) 2006-01-27 2007-08-09 Phenomix Corporation Inhibiteurs de la sérine protéase de l'hépatite c et leurs utilisations
WO2009006473A2 (fr) 2007-07-05 2009-01-08 Trustees Of Tufts College Inhibiteurs promedicaments doux de proteasome polypeptidique et methodes d'utilisation associees
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
MY161991A (en) 2007-08-06 2017-05-31 Millennium Pharm Inc Proteasome inhibitors
MX2010013642A (es) 2008-06-17 2010-12-21 Millennium Pharm Inc Compuestos de ester boronato y composiciones farmaceuticas de los mismos.
AR080863A1 (es) 2010-03-31 2012-05-16 Millennium Pharm Inc Derivados del acido1-amino-2-ciclopropiletilboronico, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer.

Also Published As

Publication number Publication date
DOP2011000086A (es) 2011-04-15
US20170349611A1 (en) 2017-12-07
JP5736314B2 (ja) 2015-06-17
KR20110082534A (ko) 2011-07-19
TW201641504A (zh) 2016-12-01
US10035811B2 (en) 2018-07-31
ECSP11011011A (es) 2011-07-29
ZA201203615B (en) 2015-03-25
BRPI0919447B1 (pt) 2021-03-30
CN103554143A (zh) 2014-02-05
JP2015143264A (ja) 2015-08-06
JP2017025091A (ja) 2017-02-02
CN103554143B (zh) 2018-02-23
US9771381B2 (en) 2017-09-26
TWI598352B (zh) 2017-09-11
EA201170508A1 (ru) 2011-10-31
BRPI0919447A2 (pt) 2015-12-15
EA030539B1 (ru) 2018-08-31
MY166653A (en) 2018-07-18
EP2346882A1 (fr) 2011-07-27
CR20160475A (es) 2016-12-19
CN102203103A (zh) 2011-09-28
SG194388A1 (en) 2013-11-29
US20140194387A1 (en) 2014-07-10
EP2346882B1 (fr) 2017-09-20
CO6362015A2 (es) 2012-01-20
CR20110216A (es) 2011-07-14
IL211983A0 (en) 2011-06-30
NZ606001A (en) 2014-08-29
CA2739375C (fr) 2019-03-12
NZ592497A (en) 2013-02-22
US8664200B2 (en) 2014-03-04
AU2009297113A1 (en) 2010-04-01
AR075090A1 (es) 2011-03-09
MX2011003317A (es) 2011-04-26
TW201024313A (en) 2010-07-01
BRPI0919447B8 (pt) 2021-05-25
UA105503C2 (uk) 2014-05-26
KR101739470B1 (ko) 2017-05-24
CL2011000653A1 (es) 2011-09-30
JP2012504122A (ja) 2012-02-16
WO2010036357A1 (fr) 2010-04-01
CA2739375A1 (fr) 2010-04-01
AU2009297113B2 (en) 2016-11-10
US20100081633A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
EA201070247A1 (ru) Ингибиторы протеасом
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
WO2007095050A3 (fr) N-hydroxyguanidines comme modulateurs de l'indolamine 2,3-dioxygénase
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
EA200802054A1 (ru) Ингибиторы фермента
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
NO20090979L (no) (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases